Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021
The vaccine adjuvants market is expected to reach USD 769.4 million by 2021 from USD 467.0 million in 2016, at a CAGR of 10.5%. The global vaccine adjuvants market is segmented based on product type, route of administration, disease type, applications, and application categories.
On the basis of type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Growth in this segment can primarily be attributed to increasing investments in research.
On the basis of route of administration, the market is segmented into subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Increasing prevalence of diseases and the need for new vaccine adjuvants with better efficacy will drive the growth of this market.
Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by the rapidly increasing aging population and rising government funding in the North American countries.
The major factors contributing to the growth of the vaccine adjuvants market include increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on improved vaccination. Furthermore, increasing R&D spending as well as acquisitions, collaborations, and agreements by companies is another major factor driving the growth of this market.
Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.
The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
On the basis of type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Growth in this segment can primarily be attributed to increasing investments in research.
On the basis of route of administration, the market is segmented into subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Increasing prevalence of diseases and the need for new vaccine adjuvants with better efficacy will drive the growth of this market.
Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by the rapidly increasing aging population and rising government funding in the North American countries.
The major factors contributing to the growth of the vaccine adjuvants market include increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on improved vaccination. Furthermore, increasing R&D spending as well as acquisitions, collaborations, and agreements by companies is another major factor driving the growth of this market.
Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.
The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccine adjuvants market. The report analyzes the vaccine adjuvants market by type, route of administration, disease type, applications, and target group
- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccine adjuvants market
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the vaccine adjuvants market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various vaccine adjuvants across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 MARKETS COVERED
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 KEY INDICATORS
2.1.1 INTRODUCTION
2.1.2 MACROINDICATORS
2.1.2.1 Rapid growth of aging population
2.1.2.2 Incidence and prevalence of cancer
2.1.2.3 Burden of infectious diseases
2.1.2.4 Healthcare expenditure patterns
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 KEY DATA FROM SECONDARY SOURCES
2.5 KEY DATA FROM PRIMARY SOURCES
2.6 KEY INDUSTRY INSIGHTS
2.7 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION
4 PREMIUM INSIGHTS
4.1 VACCINE ADJUVANTS MARKET OVERVIEW
4.2 VACCINE ADJUVANTS MARKET, BY APPLICATION
4.3 GEOGRAPHICAL SNAPSHOT OF THE VACCINE ADJUVANTS MARKET
4.4 GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY
4.5 GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE
4.6 LIFECYCLE ANALYSIS, BY REGION, 2015
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing use of adjuvants in vaccine
5.2.1.2 High prevalence of infectious and zoonotic diseases
5.2.1.3 Increase in livestock and instances of diseases
5.2.1.4 Increasing focus on immunization programs from various government bodies
5.2.1.5 Technological advancements in aluminum hydroxide-based adjuvants
5.2.1.6 Increasing focus and support on the discovery and development of vaccine adjuvants
5.2.1.7 Increasing geriatric population
5.2.2 RESTRAINTS
5.2.2.1 High cost of adjuvant research
5.2.2.2 Stringent regulatory environment and time-consuming approvals
5.2.3 OPPORTUNITIES
5.2.3.1 Combination adjuvants
5.2.3.2 Pandemic diseases
5.2.4 CHALLENGES
5.2.4.1 Identification of adjuvants
5.2.5 TRENDS
5.2.5.1 Collaborations
5.3 KEY PIPELINE PRODUCTS
5.4 REGULATORY LANDSCAPE
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.2.1 Manufacturing specifications
5.4.2.2 Routine testing
5.4.2.3 Stability
5.4.3 ASIA
5.4.4 ROW
6 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION
6.2 PARTICULATE ADJUVANTS
6.3 ADJUVANT EMULSIONS
6.4 PATHOGEN COMPONENTS
6.5 COMBINATION ADJUVANTS
6.6 OTHERS
7 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 INTRAMUSCULAR ROUTE
7.3 SUBCUTANEOUS ROUTE
7.4 INTRANASAL ROUTE
7.5 ORAL ROUTE
7.6 INTRADERMAL ROUTE
7.7 OTHERS
8 GLOBAL VACCINE ADJUVANT MARKET, BY DISEASE TYPE
8.1 INTRODUCTION
8.2 INFECTIOUS DISEASES
8.3 CANCER
8.4 OTHERS
9 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 RESEARCH APPLICATION
9.3 COMMERCIAL APPLICATION
10 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY
10.1 INTRODUCTION
10.2 HUMAN VACCINE ADJUVANTS
10.3 VETERINARY VACCINE ADJUVANTS
11 GLOBAL VACCINE ADJUVANTS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 U.K.
11.3.3 FRANCE
11.3.4 REST OF EUROPE
11.4 ASIA
11.4.1 CHINA
11.4.2 INDIA
11.4.3 REST OF ASIA
11.5 REST OF THE WORLD
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 AGREEMENTS & COLLABORATIONS
12.3.2 ACQUISITIONS
12.3.3 EXPANSIONS
12.3.4 OTHERS
13 COMPANY PROFILE
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 INTRODUCTION
13.2 BRENNTAG BIOSECTOR A/S (A SUBSIDIARY OF BRENNTAG AG)
13.3 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
13.4 CSL LIMITED
13.5 AGENUS, INC.
13.6 NOVAVAX, INC.
13.7 INVIVOGEN
13.8 SPI PHARMA, INC. (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC.)
13.9 AVANTI POLAR LIPIDS, INC.
13.10 MVP LABORATORIES INC.
13.11 OZ BIOSCIENCES
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.6 RELATED REPORTS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 MARKETS COVERED
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 KEY INDICATORS
2.1.1 INTRODUCTION
2.1.2 MACROINDICATORS
2.1.2.1 Rapid growth of aging population
2.1.2.2 Incidence and prevalence of cancer
2.1.2.3 Burden of infectious diseases
2.1.2.4 Healthcare expenditure patterns
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 KEY DATA FROM SECONDARY SOURCES
2.5 KEY DATA FROM PRIMARY SOURCES
2.6 KEY INDUSTRY INSIGHTS
2.7 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION
4 PREMIUM INSIGHTS
4.1 VACCINE ADJUVANTS MARKET OVERVIEW
4.2 VACCINE ADJUVANTS MARKET, BY APPLICATION
4.3 GEOGRAPHICAL SNAPSHOT OF THE VACCINE ADJUVANTS MARKET
4.4 GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY
4.5 GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE
4.6 LIFECYCLE ANALYSIS, BY REGION, 2015
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing use of adjuvants in vaccine
5.2.1.2 High prevalence of infectious and zoonotic diseases
5.2.1.3 Increase in livestock and instances of diseases
5.2.1.4 Increasing focus on immunization programs from various government bodies
5.2.1.5 Technological advancements in aluminum hydroxide-based adjuvants
5.2.1.6 Increasing focus and support on the discovery and development of vaccine adjuvants
5.2.1.7 Increasing geriatric population
5.2.2 RESTRAINTS
5.2.2.1 High cost of adjuvant research
5.2.2.2 Stringent regulatory environment and time-consuming approvals
5.2.3 OPPORTUNITIES
5.2.3.1 Combination adjuvants
5.2.3.2 Pandemic diseases
5.2.4 CHALLENGES
5.2.4.1 Identification of adjuvants
5.2.5 TRENDS
5.2.5.1 Collaborations
5.3 KEY PIPELINE PRODUCTS
5.4 REGULATORY LANDSCAPE
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.2.1 Manufacturing specifications
5.4.2.2 Routine testing
5.4.2.3 Stability
5.4.3 ASIA
5.4.4 ROW
6 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION
6.2 PARTICULATE ADJUVANTS
6.3 ADJUVANT EMULSIONS
6.4 PATHOGEN COMPONENTS
6.5 COMBINATION ADJUVANTS
6.6 OTHERS
7 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 INTRAMUSCULAR ROUTE
7.3 SUBCUTANEOUS ROUTE
7.4 INTRANASAL ROUTE
7.5 ORAL ROUTE
7.6 INTRADERMAL ROUTE
7.7 OTHERS
8 GLOBAL VACCINE ADJUVANT MARKET, BY DISEASE TYPE
8.1 INTRODUCTION
8.2 INFECTIOUS DISEASES
8.3 CANCER
8.4 OTHERS
9 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 RESEARCH APPLICATION
9.3 COMMERCIAL APPLICATION
10 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY
10.1 INTRODUCTION
10.2 HUMAN VACCINE ADJUVANTS
10.3 VETERINARY VACCINE ADJUVANTS
11 GLOBAL VACCINE ADJUVANTS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 U.K.
11.3.3 FRANCE
11.3.4 REST OF EUROPE
11.4 ASIA
11.4.1 CHINA
11.4.2 INDIA
11.4.3 REST OF ASIA
11.5 REST OF THE WORLD
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 AGREEMENTS & COLLABORATIONS
12.3.2 ACQUISITIONS
12.3.3 EXPANSIONS
12.3.4 OTHERS
13 COMPANY PROFILE
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 INTRODUCTION
13.2 BRENNTAG BIOSECTOR A/S (A SUBSIDIARY OF BRENNTAG AG)
13.3 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
13.4 CSL LIMITED
13.5 AGENUS, INC.
13.6 NOVAVAX, INC.
13.7 INVIVOGEN
13.8 SPI PHARMA, INC. (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC.)
13.9 AVANTI POLAR LIPIDS, INC.
13.10 MVP LABORATORIES INC.
13.11 OZ BIOSCIENCES
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.6 RELATED REPORTS
LIST OF TABLES
Table 1 INCREASING USE OF ADJUVANTS IN VACCINE-PREVENTable DISEASES DRIVES THE MARKET GROWTH
Table 2 HIGH COST OF ADJUVANT RESEARCH RESTRAINTS THE MARKET GROWTH
Table 3 COMBINED ADJUVANTS AND PANDEMIC DISEASES OFFER GROWTH OPPORTUNITIES FOR MARKET PLAYERS
Table 4 IDENTIFICATION OF ADJUVANTS CHALLENGES THE GROWTH OF THIS MARKET
Table 5 COLLABORATIONS OFFER GROWTH TRENDS FOR MARKET PLAYERS
Table 6 FDA APPROVED VACCINE ADJUVANTS
Table 7 LICENSED VACCINES CONTAINING ADJUVANTS
Table 8 EXAMPLES OF VACCINE ADJUVANTS IN CLINICAL TRIALS
Table 9 VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021
Table 10 LIST OF PARTICULATE ADJUVANTS APPROVED FOR HUMAN USE (2015)
Table 11 PARTICULATE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 12 NORTH AMERICA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 13 EUROPE PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 14 ASIA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 15 LIST OF ADJUVANT EMULSIONS APPROVED FOR HUMAN USE (2015)
Table 16 ADJUVANTS EMULSION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 17 NORTH AMERICA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 18 EUROPE ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 19 ASIA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 20 PATHOGEN COMPONENTS AND ITS DESCRIPTION
Table 21 PATHOGEN COMPONENTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 22 NORTH AMERICA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 23 EUROPE PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 24 ASIA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 25 LIST OF COMBINATION ADJUVANT APPROVED FOR HUMAN USE (2015)
Table 26 COMBINATION ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 27 NORTH AMERICA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 28 EUROPE COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 29 ASIA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 30 OTHER ADJUVANTS AND ITS DESCRIPTION
Table 31 OTHERS ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 32 NORTH AMERICA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 33 EUROPE OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 34 ASIA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 35 VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021(USD MILLION)
Table 36 INTRAMUSCULAR ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 37 SUBCUTANEOUS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 38 INTRANASAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 39 ORAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 40 INTRADERMAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 41 OTHERS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 42 VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 43 NEW CASES OF DISEASES (2014)
Table 44 INFECTIOUS DISEASES VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 45 CANCER DISEASE VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 46 OTHERS VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 47 VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 48 VACCINE ADJUVANTS MARKET, BY RESEARCH APPLICATION, BY REGION, 2014–2021(USD MILLION)
Table 49 VACCINE ADJUVANTS MARKET, BY COMMERCIAL APPLICATION, BY REGION, 2014–2021(USD MILLION)
Table 50 VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021 (USD MILLION)
Table 51 LIST OF ADJUVANTS APPROVED FOR HUMAN USE BY FDA
Table 52 HUMAN VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 53 VETERINARY VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 54 VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 55 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 56 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 57 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 58 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 59 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 60 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 61 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 62 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)
Table 63 U.S.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021, (USD MILLION)
Table 64 CANADA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021(USD MILLION)
Table 65 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 66 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 67 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 68 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 69 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021 (USD MILLION)
Table 70 GERMANY: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 71 U.K.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 72 FRANCE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 73 REST OF EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 74 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 75 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 76 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 77 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 78 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)
Table 79 CHINA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 80 INDIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 81 REST OF ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 82 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 83 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 84 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 85 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 86 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)
Table 87 AGREEMENTS & COLLABORATIONS, 2015
Table 88 ACQUISITIONS, 2015–2016
Table 89 EXPANSIONS, 2014
Table 90 OTHERS, 2014–2015
Table 1 INCREASING USE OF ADJUVANTS IN VACCINE-PREVENTable DISEASES DRIVES THE MARKET GROWTH
Table 2 HIGH COST OF ADJUVANT RESEARCH RESTRAINTS THE MARKET GROWTH
Table 3 COMBINED ADJUVANTS AND PANDEMIC DISEASES OFFER GROWTH OPPORTUNITIES FOR MARKET PLAYERS
Table 4 IDENTIFICATION OF ADJUVANTS CHALLENGES THE GROWTH OF THIS MARKET
Table 5 COLLABORATIONS OFFER GROWTH TRENDS FOR MARKET PLAYERS
Table 6 FDA APPROVED VACCINE ADJUVANTS
Table 7 LICENSED VACCINES CONTAINING ADJUVANTS
Table 8 EXAMPLES OF VACCINE ADJUVANTS IN CLINICAL TRIALS
Table 9 VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021
Table 10 LIST OF PARTICULATE ADJUVANTS APPROVED FOR HUMAN USE (2015)
Table 11 PARTICULATE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 12 NORTH AMERICA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 13 EUROPE PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 14 ASIA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 15 LIST OF ADJUVANT EMULSIONS APPROVED FOR HUMAN USE (2015)
Table 16 ADJUVANTS EMULSION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 17 NORTH AMERICA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 18 EUROPE ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 19 ASIA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 20 PATHOGEN COMPONENTS AND ITS DESCRIPTION
Table 21 PATHOGEN COMPONENTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 22 NORTH AMERICA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 23 EUROPE PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 24 ASIA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 25 LIST OF COMBINATION ADJUVANT APPROVED FOR HUMAN USE (2015)
Table 26 COMBINATION ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 27 NORTH AMERICA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 28 EUROPE COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 29 ASIA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 30 OTHER ADJUVANTS AND ITS DESCRIPTION
Table 31 OTHERS ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 32 NORTH AMERICA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 33 EUROPE OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 34 ASIA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)
Table 35 VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021(USD MILLION)
Table 36 INTRAMUSCULAR ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 37 SUBCUTANEOUS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 38 INTRANASAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 39 ORAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 40 INTRADERMAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 41 OTHERS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 42 VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 43 NEW CASES OF DISEASES (2014)
Table 44 INFECTIOUS DISEASES VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 45 CANCER DISEASE VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 46 OTHERS VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 47 VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 48 VACCINE ADJUVANTS MARKET, BY RESEARCH APPLICATION, BY REGION, 2014–2021(USD MILLION)
Table 49 VACCINE ADJUVANTS MARKET, BY COMMERCIAL APPLICATION, BY REGION, 2014–2021(USD MILLION)
Table 50 VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021 (USD MILLION)
Table 51 LIST OF ADJUVANTS APPROVED FOR HUMAN USE BY FDA
Table 52 HUMAN VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 53 VETERINARY VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)
Table 54 VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 55 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 56 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 57 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 58 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 59 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 60 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 61 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 62 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)
Table 63 U.S.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021, (USD MILLION)
Table 64 CANADA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021(USD MILLION)
Table 65 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 66 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 67 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 68 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 69 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021 (USD MILLION)
Table 70 GERMANY: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 71 U.K.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 72 FRANCE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 73 REST OF EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 74 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 75 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 76 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 77 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 78 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)
Table 79 CHINA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 80 INDIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 81 REST OF ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 82 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 83 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)
Table 84 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)
Table 85 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)
Table 86 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)
Table 87 AGREEMENTS & COLLABORATIONS, 2015
Table 88 ACQUISITIONS, 2015–2016
Table 89 EXPANSIONS, 2014
Table 90 OTHERS, 2014–2015
LIST OF FIGURES
Figure 1 RESEARCH DESIGN
Figure 2 INCREASE IN AGING POPULATION, BY COUNTRY (2010 VS. 2015)
Figure 3 PERCENTAGE INCREASE IN AGING POPULATION, BY REGION (1980–2010 VS. 2010–2040)
Figure 4 GLOBAL BURDEN OF CANCER, BY REGION (2005–2030)
Figure 5 NUMBER OF NEW CANCER CASES BY COUNTRY
Figure 6 HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES, 2000 VS. 2012
Figure 7 HEALTHCARE SPENDING MATRIX, BY COUNTRY (2013)
Figure 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
Figure 9 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
Figure 10 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 11 DATA TRIANGULATION METHODOLOGY
Figure 12 VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2016 VS. 2021 (USD MILLION)
Figure 13 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2016 VS. 2021 (USD MILLION)
Figure 14 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2016 VS. 2021 (USD MILLION)
Figure 15 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
Figure 16 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2016 VS. 2021 (USD MILLION)
Figure 17 GLOBAL VACCINE ADJUVANTS MARKET, BY REGION, 2016 (USD MILLION)
Figure 18 THE VACCINE ADJUVANTS MARKET IS EXPECTED TO SHOWCASE HIGH GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD
Figure 19 THE RESEARCH APPLICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
Figure 20 ASIAN COUNTRIES ARE EXPECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 21 THE HUMAN VACCINE ADJUVANTS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 22 THE INFECTIOUS DISEASE SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2021
Figure 23 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD
Figure 24 THE PARTICULATE ADJUVANTS SEGMENT IS THE LARGEST SEGMENT OF THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021
Figure 25 THE INTRANASAL ROUTE OF ADMINISTRATION SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD FROM 2016 TO 2021
Figure 26 THE CANCER DISEASE TYPE SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 27 CANCER INCIDENCE, BY REGION, 2012–2020
Figure 28 THE RESEARCH APPLICATION SEGMENT IS THE LARGEST IN THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021
Figure 29 HUMAN VACCINE ADJUVANTS ACCOUNTS FOR THE LARGEST SHARE IN VACCINE ADJUVANT MARKET, BY APPLICATION CATEGORY, IN 2016
Figure 30 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD
Figure 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT
Figure 32 EUROPEAN VACCINE ADJUVANTS MARKET SNAPSHOT
Figure 33 ASIA: VACCINE ADJUVANTS MARKET SNAPSHOT
Figure 34 AGREEMENTS & COLLABORATIONS WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS, 2013–2016
Figure 35 GLOBAL VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015
Figure 36 BATTLE FOR MARKET SHARE: AGREEMENTS & COLLABORATIONS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS
Figure 37 PRODUCT BENCHMARKING FOR MAJOR PLAYERS
Figure 38 COMPANY SNAPSHOT: BRENNTAG AG
Figure 39 COMPANY SNAPSHOT: AIR LIQUIDE GROUP
Figure 40 COMPANY SNAPSHOT: CSL LIMITED
Figure 41 COMPANY SNAPSHOT: AGENUS, INC.
Figure 42 COMPANY SNAPSHOT: NOVAVAX, INC.
Figure 1 RESEARCH DESIGN
Figure 2 INCREASE IN AGING POPULATION, BY COUNTRY (2010 VS. 2015)
Figure 3 PERCENTAGE INCREASE IN AGING POPULATION, BY REGION (1980–2010 VS. 2010–2040)
Figure 4 GLOBAL BURDEN OF CANCER, BY REGION (2005–2030)
Figure 5 NUMBER OF NEW CANCER CASES BY COUNTRY
Figure 6 HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES, 2000 VS. 2012
Figure 7 HEALTHCARE SPENDING MATRIX, BY COUNTRY (2013)
Figure 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
Figure 9 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
Figure 10 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 11 DATA TRIANGULATION METHODOLOGY
Figure 12 VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2016 VS. 2021 (USD MILLION)
Figure 13 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2016 VS. 2021 (USD MILLION)
Figure 14 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2016 VS. 2021 (USD MILLION)
Figure 15 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
Figure 16 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2016 VS. 2021 (USD MILLION)
Figure 17 GLOBAL VACCINE ADJUVANTS MARKET, BY REGION, 2016 (USD MILLION)
Figure 18 THE VACCINE ADJUVANTS MARKET IS EXPECTED TO SHOWCASE HIGH GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD
Figure 19 THE RESEARCH APPLICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
Figure 20 ASIAN COUNTRIES ARE EXPECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 21 THE HUMAN VACCINE ADJUVANTS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 22 THE INFECTIOUS DISEASE SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2021
Figure 23 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD
Figure 24 THE PARTICULATE ADJUVANTS SEGMENT IS THE LARGEST SEGMENT OF THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021
Figure 25 THE INTRANASAL ROUTE OF ADMINISTRATION SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD FROM 2016 TO 2021
Figure 26 THE CANCER DISEASE TYPE SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 27 CANCER INCIDENCE, BY REGION, 2012–2020
Figure 28 THE RESEARCH APPLICATION SEGMENT IS THE LARGEST IN THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021
Figure 29 HUMAN VACCINE ADJUVANTS ACCOUNTS FOR THE LARGEST SHARE IN VACCINE ADJUVANT MARKET, BY APPLICATION CATEGORY, IN 2016
Figure 30 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD
Figure 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT
Figure 32 EUROPEAN VACCINE ADJUVANTS MARKET SNAPSHOT
Figure 33 ASIA: VACCINE ADJUVANTS MARKET SNAPSHOT
Figure 34 AGREEMENTS & COLLABORATIONS WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS, 2013–2016
Figure 35 GLOBAL VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015
Figure 36 BATTLE FOR MARKET SHARE: AGREEMENTS & COLLABORATIONS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS
Figure 37 PRODUCT BENCHMARKING FOR MAJOR PLAYERS
Figure 38 COMPANY SNAPSHOT: BRENNTAG AG
Figure 39 COMPANY SNAPSHOT: AIR LIQUIDE GROUP
Figure 40 COMPANY SNAPSHOT: CSL LIMITED
Figure 41 COMPANY SNAPSHOT: AGENUS, INC.
Figure 42 COMPANY SNAPSHOT: NOVAVAX, INC.
